TY  - CONF
AU  - Puerta, JM
AU  - Jiménez Velasco, A
AU  - García, MJ
AU  - Molina, JR
AU  - Ruiz, C
AU  - Ferrer, C
AU  - Durán, MS
AU  - Simón, I
AU  - Clavero, E
AU  - Avellaneda, MC
AU  - Rosell, A
AU  - Ballesteros, I
AU  - Ramírez, S
AU  - Portero, MA
AU  - Ramírez, MJ
AU  - Fernández, M
AU  - Jiménez, M
AU  - Fe, R
AU  - Mulero, N
AU  - López, P
PY  - 2016
SN  - 0390-6078
UR  - http://hdl.handle.net/10668/2445
T2  - Haematologica
AB  - Even though they were approved last June 2011 to be used on first line, it is not a common procedure to begin treatment of CML-CP with 2GTKI, despite it has been demonstrated its efficacy and safety against imatinibon ENESTnd and Dasision clinical...
LA  - en
PB  - Ferrata Storti Foundation
KW  - Dasatinib
KW  - Humanos
KW  - Mesilato de imatinib
KW  - Leucemia mielogenosa crónica BCR-ABL positiva
KW  - Pirimidinas
KW  - Sistema de registros
KW  - Andalucía
KW  - Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Thiazoles::Dasatinib
KW  - Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
KW  - Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Benzamides::Imatinib Mesylate
KW  - Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries
TI  - Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC)
TY  - conference presentation
ER  -